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What is an Abnormal Blood Glucose Level?
Combining Lessons From Epidemiology and In Vivo Plaque Imaging*
Ramachandran S. Vasan, MD, FACC
Boston, Massachusetts. . . the idea of a sharp distinction between health and
disease is a medical artefact for which nature, if
consulted, provides no support.
Geoffrey Rose (1)
Notions of what constitutes a normal blood glucose
level have evolved rapidly over the last 2 decades.
We have transitioned from a binary classification of
glycemic disorders—individuals with and without
diabetes—to a widely accepted concept that there is
a continuous gradient of health risks across the
range of blood glucose (2). This concept is impor-
tant for several reasons. First, the mounting burden
of obesity worldwide is fuelling a concomitant
burden of impaired glucose homeostasis (IGH, a
term that combines impaired fasting glucose and
impaired glucose tolerance [IGT]) and diabetes.
The global prevalence of diabetes will increase from
171 million in 2000 to 366 million by 2030 (3),
whereas that of IGT will increase from 197
See page 39
million to 420 million (4). Second, although diabe-
tes accounts for nearly 1 million deaths worldwide
every year, an additional 2.2 million cardiovascular
(CVD) deaths are attributable to higher-than-
optimal levels of blood glucose (5). In other words,
diabetes is only the tip of the iceberg when it comes
*Editorials published in the JACC: Cardiovascular Imaging reflect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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2K24HL04334.to burden of disease caused by suboptimal blood
glucose. Third, the continuous gradient of health
risks posed by blood glucose levels suggests that
intervention at the onset of diabetes represents the
failure of prevention, which is best begun much
earlier along the disease continuum.
Evidence for Continuous Gradient of
Health Risks Across Blood Glucose Levels
Meta-analyses of epidemiologic studies suggest that
there is a continuous gradient of risk across blood
glucose levels (fasting and post-load) for the incidence
of diabetes, CVD, and mortality (6,7). A 1-mmol/l
lower fasting blood glucose level is associated with an
approximately 20% lower risk of CVD (6). Whereas
IGH increases the risk of diabetes, recent data suggest
that such risk may begin at blood glucose levels
considered normal (8), probably because beta cell
dysfunction occurs early (2).
Why and How Does Impaired Glucose
Homeostasis Pose Vascular Risk?
The continuous gradient of risk associated with
blood glucose may have several explanations. First,
mild elevations of blood glucose portend future
tracking to higher levels, including diabetes. Sec-
ond, risk factors cluster, and it may be the sum of
risk factors that may cause and/or compound the
hazard. Third, hyperglycemia and/or insulin resis-
tance may both be atherogenic. Data from the
Nurses Health Study (9) suggest that women des-
tined to develop diabetes experienced a 3-fold
increased risk of CVD 10 to 15 years before the
onset of diabetes, corroborating the hypothesis that
the “clock starts ticking” very early (10).
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47lycemia and Plaque Biology:
s There a Continuous Gradient of Risk?
n this issue of JACC: Cardiovascular Imaging, Amano
t al. (11) use in vivo plaque characterization with
ntravascular ultrasound to study a group of older
ndividuals with IGH. The study focused on target
esions in individuals undergoing percutaneous coro-
ary interventions, one-quarter in the setting of an
cute coronary syndrome. About 25% of the patients
ad a prior myocardial infarction, and nearly one-half
ad multivessel coronary disease. The investigators
oted a 4-fold increased odds of lipid-rich plaques in
ndividuals with IGH, a magnitude of association
imilar to that for diabetes. Of interest, a gradient of a
igher prevalence of lipid-rich plaques was observed
cross insulin resistance tertiles.
On the face of it, the investigation provides
triking support to the aforementioned epidemi-
logic data. But several caveats are worth noting.
he investigators studied an elderly catheteriza-
ion laboratory sample with a high burden of
revalent disease. The investigators acknowledge
hat they studied culprit plaques after their rup-
ure. Thus, the study does not establish that
verage community-dwelling individuals with
GH have a greater burden of vulnerable plaques.
owever, the study is consistent with substantial
xperimental evidence.
Hyperglycemia adversely affects vascular cells and
he cell–cell interactions that mediate atherogenesis
2,12). A greater leukocyte adhesion to endothelial
ells occurs because of up-regulation of adhesion
olecules and activation of protein kinase C and
he transcriptional factor nuclear factor kappa B.
dvanced glycation end products enhance mono-
yte migration, cytokine production, oxidant stress,
nd foam cell formation and increase vascular per-
eability and endothelial dysfunction. Nonenzy-
atic glycation can alter circulating lipoproteins
nd can modify proteins in the vascular basement
embranes, thereby facilitating prolonged intimal
ontact of modified low-density lipoproteins and
acrophages (the latter via scavenger receptor class
), which in turn enhances generation of oxidized
ow-density lipoprotein and lipid insudation into
he plaque. Hyperglycemia also causes platelet dys-
unction, promotes hypercoagulability, and reduces
ascular distensibility.
Insulin resistance may be atherogenic via several
echanisms independent of hyperglycemia (12).
nsulin receptors are present on the cells involved in
therogenesis, such as endothelial cells, macro- lhages, and vascular smooth cells, and T cells can
xpress these receptors on antigen presentation
12). Insulin resistance impairs vascular nitric oxide
roduction, is proinflammatory, impairs fibrinoly-
is, and increases endothelin production (12).
hat Is an Abnormal Blood Glucose Level,
nd What Are the Implications for Prevention?
he data reviewed in the previous text suggest that
n abnormal blood glucose level is best regarded as
a level for which there is scientific evidence that
enefits of intervention outweigh potential harm,”
nalogous to how Evans and Rose (13) defined
ypertension. The implication is that an abnormal
lucose level is not confined to those who meet the
riteria for diabetes or IGH. Clinical trials have
hown that diabetes is preventable by lifestyle in-
erventions and by pharmacological means in indi-
iduals with IGH (14–16). Data are lacking, how-
ver, to show that such interventions reduce the
ncreased CVD risk in IGH. Thresholds that define
n abnormal blood glucose level and the choice of
nterventions are likely to be dictated by absolute
isks, efficacy and cost-effectiveness of interventions
t different thresholds, budgetary considerations,
nd constraints of health care delivery systems (17).
iven the large segment of the population that falls
nto the IGH category, additional research is war-
anted to evaluate whether imaging and nonimag-
ng tests can be used to further risk stratify this
roup to select a high-risk subgroup for interven-
ion. Such tests should be simple, reproducible,
alidated, and cost effective.
The data presented herein argue also for con-
idering fasting blood glucose level as a compo-
ent of CVD risk prediction algorithms, as op-
osed to the currently available instruments that
abel diabetes as a risk equivalent but ignore lesser
egrees of IGH.
A critical component to stemming the burgeon-
ng global epidemic of IGH is tackling the problem
f overweight and obesity (4). This requires initia-
ives both at the individual and at the societal levels
4). The latter must include policy directed at
romoting affordable healthier foods, nonmotor-
zed transportation and opportunities for exercise,
ealth screening, and health education.
onclusions
ccumulating evidence suggests that IGH is a
ife-course disease that evolves over a period of
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48ecades, with excess adiposity, insulin resistance,
nd beta-cell failure as the underlying substrates.
herefore, prevention of diabetes and its precursors
s best achieved by a long-term approach that
ombines lifestyle measures targeted at maintaining
ptimal body weight in all persons, with appropri-368:1651–9. sociated with lipigh-risk individuals who are further along the
pectrum of IGH.
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venue, Suite 2, Framingham, Massachusetts 01702-ate pharmacological measures being directed at 5803. E-mail: vasan@bu.edu.1
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